510(k) · Radiology

Autoplaque

by Cedars-Sinai Medical Center: AIM

Autoplaque is an AI-enabled medical device from Cedars-Sinai Medical Center: AIM that the U.S. FDA cleared through 510(k) K212758 on May 19, 2023. Its lead review panel is Radiology and its primary product code is LLZ (System, Image Processing, Radiological).

See also FDA-cleared AI radiology devices in 2023, all FDA AI clearances in 2023, top radiology AI devices.

Key facts

Submission numberK212758
Pathway510(k)
Date of final decision
Company (FDA list)Cedars-Sinai Medical Center: AIM
Lead review panelRadiology
Primary product codeLLZ — System, Image Processing, Radiological
Applicant (openFDA)Cedars-Sinai Medical Center: Aim
Applicant locationLos Angeles, CA, US
Device classClass 2
Regulation number21 CFR 892.2050
Decision codeSESE
Submission typeTraditional

Source: FDA AI-Enabled Medical Devices list and openFDA.

What this means

A 510(k) is a premarket submission showing the device is substantially equivalent to a legally marketed predicate device. A cleared 510(k) means FDA agreed with that equivalence. Autoplaque went through this pathway (K212758).

openFDA lists it as a Class 2 device under 21 CFR 892.2050. Class II devices are moderate risk and are subject to general and special controls.

Product code LLZ covers 161 devices on the FDA AI list. By decision date, this device is #128 of 161 under that code. Cedars-Sinai Medical Center: AIM has 1 AI-enabled device on the list, and the Radiology panel accounts for 1,230 in total.

Being on this list doesn't describe how well the device works clinically. Check the FDA record for its indications for use.

Similar devices (product code LLZ)